612 related articles for article (PubMed ID: 19875543)
21. Goals of treatment for type 2 diabetes: beta-cell preservation for glycemic control.
Marchetti P; Lupi R; Del Guerra S; Bugliani M; D'Aleo V; Occhipinti M; Boggi U; Marselli L; Masini M
Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S178-83. PubMed ID: 19875548
[No Abstract] [Full Text] [Related]
22. Effect of vitamin D supplementation on oral glucose tolerance in individuals with low vitamin D status and increased risk for developing type 2 diabetes (EVIDENCE): A double-blind, randomized, placebo-controlled clinical trial.
Moreira-Lucas TS; Duncan AM; Rabasa-Lhoret R; Vieth R; Gibbs AL; Badawi A; Wolever TM
Diabetes Obes Metab; 2017 Jan; 19(1):133-141. PubMed ID: 27717236
[TBL] [Abstract][Full Text] [Related]
23. Progressive erosion of β-cell function precedes the onset of hyperglycemia in the NOD mouse model of type 1 diabetes.
Ize-Ludlow D; Lightfoot YL; Parker M; Xue S; Wasserfall C; Haller MJ; Schatz D; Becker DJ; Atkinson MA; Mathews CE
Diabetes; 2011 Aug; 60(8):2086-91. PubMed ID: 21659497
[TBL] [Abstract][Full Text] [Related]
24. Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents.
Kohnert KD; Augstein P; Zander E; Heinke P; Peterson K; Freyse EJ; Hovorka R; Salzsieder E
Diabetes Care; 2009 Jun; 32(6):1058-62. PubMed ID: 19244086
[TBL] [Abstract][Full Text] [Related]
25. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients.
Muscelli E; Mari A; Casolaro A; Camastra S; Seghieri G; Gastaldelli A; Holst JJ; Ferrannini E
Diabetes; 2008 May; 57(5):1340-8. PubMed ID: 18162504
[TBL] [Abstract][Full Text] [Related]
26. Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes.
Gastaldelli A; Casolaro A; Pettiti M; Nannipieri M; Ciociaro D; Frascerra S; Buzzigoli E; Baldi S; Mari A; Ferrannini E
Clin Pharmacol Ther; 2007 Feb; 81(2):205-12. PubMed ID: 17259945
[TBL] [Abstract][Full Text] [Related]
27. Defining the role of insulin lispro in the management of postprandial hyperglycaemia in patients with type 2 diabetes mellitus.
Giugliano D; Ceriello A; Razzoli E; Esposito K
Clin Drug Investig; 2008; 28(4):199-210. PubMed ID: 18345710
[TBL] [Abstract][Full Text] [Related]
28. Pathophysiology of prediabetes.
Bhansali A; Dutta P
J Indian Med Assoc; 2005 Nov; 103(11):594-5, 599. PubMed ID: 16570762
[TBL] [Abstract][Full Text] [Related]
29. Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going.
DeFronzo RA
Am J Med; 2010 Mar; 123(3 Suppl):S38-48. PubMed ID: 20206731
[TBL] [Abstract][Full Text] [Related]
30. Fate of the beta-cell in the pathophysiology of type 2 diabetes.
Campbell RK
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360
[TBL] [Abstract][Full Text] [Related]
31. Exenatide Treatment Alone Improves β-Cell Function in a Canine Model of Pre-Diabetes.
Ionut V; Woolcott OO; Mkrtchyan HJ; Stefanovski D; Kabir M; Iyer MS; Liu H; Castro AV; Wu Q; Broussard JL; Kolka CM; Asare-Bediako I; Bergman RN
PLoS One; 2016; 11(7):e0158703. PubMed ID: 27398720
[TBL] [Abstract][Full Text] [Related]
32. Novel canine models of obese prediabetes and mild type 2 diabetes.
Ionut V; Liu H; Mooradian V; Castro AV; Kabir M; Stefanovski D; Zheng D; Kirkman EL; Bergman RN
Am J Physiol Endocrinol Metab; 2010 Jan; 298(1):E38-48. PubMed ID: 19843874
[TBL] [Abstract][Full Text] [Related]
33. Heterogeneous relationship of early insulin response and fasting insulin level with development of non-insulin-dependent diabetes mellitus in non-diabetic Japanese subjects with or without obesity.
Yoshinaga H; Kosaka K
Diabetes Res Clin Pract; 1999 May; 44(2):129-36. PubMed ID: 10414932
[TBL] [Abstract][Full Text] [Related]
34. Enhancement of postprandial endogenous insulin secretion rather than exogenous insulin injection ameliorated insulin antibody-induced unstable diabetes: a case report.
Kaneko K; Satake C; Izumi T; Tanaka M; Yamamoto J; Asai Y; Sawada S; Imai J; Yamada T; Katagiri H
BMC Endocr Disord; 2019 Jan; 19(1):5. PubMed ID: 30621663
[TBL] [Abstract][Full Text] [Related]
35. Relationship between insulin resistance and β-cell dysfunction in subphenotypes of prediabetes and type 2 diabetes.
Færch K; Johansen NB; Witte DR; Lauritzen T; Jørgensen ME; Vistisen D
J Clin Endocrinol Metab; 2015 Feb; 100(2):707-16. PubMed ID: 25387263
[TBL] [Abstract][Full Text] [Related]
36. Point: a glucose tolerance test is important for clinical practice.
Tuomilehto J
Diabetes Care; 2002 Oct; 25(10):1880-2. PubMed ID: 12351496
[No Abstract] [Full Text] [Related]
37. Defining the role of basal and prandial insulin for optimal glycemic control.
Horton ES
J Am Coll Cardiol; 2009 Feb; 53(5 Suppl):S21-7. PubMed ID: 19179213
[TBL] [Abstract][Full Text] [Related]
38. FASTING VERSUS POSTPRANDIAL HYPERGLYCEMIA AS A TREATMENT TARGET TO LOWER ELEVATED HEMOGLOBIN A1C.
Shaefer C; Reid T; Vlajnic A; Zhou R; DiGenio A
Endocr Pract; 2015 Dec; 21(12):1323-32. PubMed ID: 26307902
[TBL] [Abstract][Full Text] [Related]
39. The role of blood glucose-lowering drugs in the light of the UKPDS. United Kingdom Prospective Diabetes Study.
Monnier L
Diabetes Obes Metab; 1999 Sep; 1 Suppl 2():S14-23. PubMed ID: 11221798
[No Abstract] [Full Text] [Related]
40. Impaired beta-cell sensitivity to glucose and maximal insulin secretory capacity in adolescents with type 2 diabetes.
Elder DA; Woo JG; D'Alessio DA
Pediatr Diabetes; 2010 Aug; 11(5):314-21. PubMed ID: 19961550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
